ライフサイエンスコーパス: myeloid differentiation

1 d-specific genes in a manner correlated with myeloid differentiation.

2 the importance of C/EBPalpha acetylation in myeloid differentiation.

3 ranscription cascade ultimately resulting in myeloid differentiation.

4 s and the diabetes-induced propensity toward myeloid differentiation.

5 Hox-mediated activation of Meis1 suppresses myeloid differentiation.

6 CDK6 depletion is mediated through enhanced myeloid differentiation.

7 phosphorylation, increased p53 activity, and myeloid differentiation.

8 ster regulator of hematopoiesis and promotes myeloid differentiation.

9 n and leads to a reduced CD11b expression in myeloid differentiation.

10 -damage accumulation, coupled with increased myeloid differentiation.

11 nscription factor PU.1 controls lymphoid and myeloid differentiation.

12 y 5, member a (Clec5a), which is involved in myeloid differentiation.

13 tes myeloid progenitor expansion and impedes myeloid differentiation.

14 used to shed new light on the mechanisms for myeloid differentiation.

15 deficiency leads to MPD through compensatory myeloid differentiation.

16 ge colony-stimulating factor (M-CSF)-induced myeloid differentiation.

17 oes not induce caspase 8 activity to promote myeloid differentiation.

18 pamycin complex 1 as a critical regulator of myeloid differentiation.

19 ed to the study of the mechanisms underlying myeloid differentiation.

20 elf-renewal, causes lineage bias, and blocks myeloid differentiation.

21 tion between DCs and CD4 T cells to regulate myeloid differentiation.

22 current DNA copy gains in leukemia, controls myeloid differentiation.

23 SPC, it was intrinsically required for their myeloid differentiation.

24 Myc function or sterol biosynthesis impaired myeloid differentiation.

25 ;17), or t(8;21) and is downregulated during myeloid differentiation.

26 upstream regulator of KDR activation during myeloid differentiation.

27 s mainly involved in cell fate decisions for myeloid differentiation.

28 igated its transcriptional activation during myeloid differentiation.

29 lements of identity and function in terminal myeloid differentiation.

30 e in the transcriptional program that drives myeloid differentiation.

31 HoxA9, a gene normally downregulated during myeloid differentiation.

32 Myeloid differentiation-2 (MD-2) acts as an essential co

33 ng in vitro and their direct binding to TLR4-myeloid differentiation-2 (MD-2) complex by photolabelin

34 Myeloid differentiation 88 (MyD88) is the key signaling

35 ate the caspase 3 activity needed to promote myeloid differentiation, a key process in the viral diss

36 iduals resulted in markedly reduced in vitro myeloid differentiation accompanied by cell-cycle arrest

37 and high levels of Ly6G, a component of the myeloid differentiation Ag Gr-1, are also highly expande

38 ch suggests the effect of FLT3 inhibition on myeloid differentiation and a manifestation of a broader

39 This manifests as a block in myeloid differentiation and an increase in malignant sel

40 cultures and IL-6R neutralization inhibited myeloid differentiation and decreased mycobacterial grow

41 We also apply the algorithm to mouse myeloid differentiation and demonstrate its generalizati

42 h the AML-ETO9a fusion oncoprotein to impair myeloid differentiation and enhance leukemia stem cell (

43 ription factor PU.1 is a master regulator of myeloid differentiation and function.

44 L-6 is a particularly important regulator of myeloid differentiation and HSPC proliferation in a para

45 mber A signaling to SRF, results in aberrant myeloid differentiation and hyperactivity of the immune

46 t DNA methylation is markedly altered during myeloid differentiation and identifies critical regions

47 stemic reduction of EPO in the host enhanced myeloid differentiation and improved BM homing of UCB CD

48 cating Asxl1 mutations (ASXL1-MTs) inhibited myeloid differentiation and induced MDS-like disease in

49 s, confirm that KLF4 overexpression promotes myeloid differentiation and inhibits cell proliferation

50 hat reintroducing miR-150 expression induces myeloid differentiation and inhibits proliferation of AM

51 scription factor C/EBPalpha is essential for myeloid differentiation and is frequently dysregulated i

52 factor C/EBPalpha is a critical mediator of myeloid differentiation and is often functionally impair

53 8), an integral transcriptional component of myeloid differentiation and lineage commitment.

54 scriptional repression of genes critical for myeloid differentiation and maturation.

55 our understanding of the sheer diversity of myeloid differentiation and phenotypic regulation.

56 t Forkhead box class O genes (FoxOs) inhibit myeloid differentiation and prevent differentiation of l

57 factors, particularly CEBPalpha, involved in myeloid differentiation and retinoid responsiveness.

58 kaemic effects, including increased terminal myeloid differentiation and suppression of leukaemia gro

59 g for stem cell development and maintenance, myeloid differentiation, and apoptosis.

60 , including impaired proliferation, enhanced myeloid differentiation, and depletion of LSCs.

61 cancer and stromal cells and, subsequently, myeloid differentiation antigen-positive (Gr-1(+)) myelo

62 esults indicate that C/EBPgamma mediates the myeloid differentiation arrest induced by C/EBPalpha def

63 it did increase H3K4(me2) and expression of myeloid-differentiation-associated genes.

64 inappropriately expressed, delays or blocks myeloid differentiation at least in part by DNA hypermet

65 ct the expansion, increased self-renewal, or myeloid differentiation bias in Nras(G12D/+) HSCs.

66 CCR2(-)CD150(+)CD48(-) LSK cells, displays a myeloid differentiation bias, and dominates the migrator

67 expansion of hematopoietic progenitors, and myeloid differentiation bias.

68 Moreover, miR-9 expression reverses a myeloid differentiation block that is induced by EVI1.

69 tant WT1 in CD34(+) cord blood cells induced myeloid differentiation block.

70 g cells in recipient mice with an unexpected myeloid differentiation blockade and lymphoid-lineage bi

71 hus, LBR plays a critical role in regulating myeloid differentiation, but how the two functional doma

72 y, is known to be involved in osteoblast and myeloid differentiation, but its role in lineage commitm

73 n of the gene encoding Triad1 (ARIH2) during myeloid differentiation, but the contribution of increas

74 optosis, TNF-alpha promotes HSC survival and myeloid differentiation by activating a strong and speci

75 /megakaryocyte progenitors but with residual myeloid differentiation capacity; "E-MEP," strongly bias

76 of the mechanisms underlying the diminished myeloid differentiation caused by reduced SLPI levels re

77 expression by direct promoter binding during myeloid differentiation, enforced expression of miR-182

78 IFNgamma, MCP1, MIP1alpha, and TNFalpha) and myeloid differentiation factor (Endoglin) were increased

79 Although in mammals the TLR4/myeloid differentiation factor (MD)2/CD14 complex is res

80 ecognition by the human Toll-like receptor 4-myeloid differentiation factor 2 (hTLR4-MD2) complex, al

81 ctivation of the Toll-like Receptor 4 (TLR4)-myeloid differentiation factor 2 (MD-2) complex, which r

82 t productively engage the mouse TLR4 (mTLR4)/myeloid differentiation factor 2 (MD-2) complex.

83 Myeloid differentiation factor 2 (MD-2) is an extracellu

84 The human TLR4.myeloid differentiation factor 2 (MD-2) LPS receptor com

85 nstrate that the extracellular TLR4 adaptor, myeloid differentiation factor 2 (MD-2), binds specifica

86 by endotoxin presented as a monomer bound to myeloid differentiation factor 2 (MD-2).

87 ated through the Toll-like receptor 4 (TLR4)-myeloid differentiation factor 2 (MD2) complex.

88 Dimerization of Toll-like receptor 4 (TLR4)/myeloid differentiation factor 2 (MD2) heterodimers is c

89 phisms on TLR4 expression, interactions with myeloid differentiation factor 2 (MD2), LPS binding, and

90 tivation of LPS-induced Toll-like receptor 4-myeloid differentiation factor 2 (TLR4/MD2).

91 host receptors like the Toll-like receptor 4/myeloid differentiation factor 2 complex (TLR4/MD-2), mo

92 saccharide binding to a toll-like receptor-4/myeloid differentiation factor 2 fusion protein.

93 tent ligand of the Toll-like receptor (TLR)4/myeloid differentiation factor 2 receptor of the innate

94 ice lacking both Lyn and the adaptor protein myeloid differentiation factor 88 (MyD88) in DCs, specif

95 ial Toll-like receptor (TLR) adaptor protein myeloid differentiation factor 88 (MyD88) in systemic an

96 Myeloid differentiation factor 88 (MyD88) is an adaptor

97 Signaling through myeloid differentiation factor 88 (MyD88) is critical fo

98 Myeloid differentiation factor 88 (MYD88) L265P somatic

99 , Cunha et al. now describe a novel role for myeloid differentiation factor 88 (MyD88) signaling in s

100 Furthermore, B cell-intrinsic expression of myeloid differentiation factor 88 (MyD88) was required t

101 of which signal through the adaptor protein myeloid differentiation factor 88 (MyD88), have been sug

102 pe I IFN expression proceeded independent of myeloid differentiation factor 88 (MyD88), which is the

103 umbers in a Toll-like receptor 4 (TLR4)- and myeloid differentiation factor 88 (MyD88)-dependent mann

104 deletion of the inflammatory adaptor protein myeloid differentiation factor 88 (MyD88).

105 or 3 (TLR3), signal via the adaptor molecule myeloid differentiation factor 88 (MyD88).

106 toll-like receptor 4 (TLR4) and its adaptor myeloid differentiation factor 88 (MyD88).

107 Using myeloid differentiation factor 88 (MyD88)/TIR-domain-con

108 r p65 translocation, and colocalization with myeloid differentiation factor 88 and calcium-modulating

109 as a scaffold to promote the interaction of myeloid differentiation factor 88 and IL-1R-associated k

110 equent increases in the downstream molecules myeloid differentiation factor 88 and NF-kB.

111 ectly targeted Th17 cells by down-regulating myeloid differentiation factor 88 expression to suppress

112 Toll-like receptor signaling through myeloid differentiation factor 88 maintains segregation

113 ts from mice with genetic deletion of MyD88 (myeloid differentiation factor 88) or TLRs (Toll-like re

114 Myeloid differentiation factor 88-deficient (MyD88(-/-))

115 on are uncertain, although a role for a TLR4/myeloid differentiation factor 88-dependent pathway lead

116 by the microbiota via Toll-like receptor and myeloid differentiation factor 88-mediated signalling pa

117 hese outcomes by using the signaling adaptor myeloid differentiation factor 88.

118 onstrate that NQO1 controls the stability of myeloid differentiation factor C/EBPalpha against 20S pr

119 20 S proteasome and NQO2 both interact with myeloid differentiation factor CCAAT-enhancer-binding pr

120 signaling through the IL-33 receptor ST2 and myeloid differentiation factor MyD88 is essential for de

121 schlafen 4 (Slfn4) as a GLI1 target gene and myeloid differentiation factor that correlates with spas

122 racted with the LPS receptors, CD14 and TLR4/myeloid differentiation factor-2 (MD-2) complex, indicat

123 In this study, we demonstrated that myeloid differentiation factor-2 (MD-2) is also tyrosine

124 ctions in complex with its accessory protein myeloid differentiation factor-2 (MD-2), is a therapeuti

125 receptor 4 (TLR4), along with its coreceptor myeloid differentiation factor-2 (MD-2), mediates these

126 In this article, we identify myeloid differentiation factor-2 (MD-2), the coreceptor

127 PS is recognized by the Toll-like receptor 4/myeloid differentiation factor-2 (TLR4/MD2) complex, lea

128 Here, we show that Myeloid differentiation factor-2-related lipid-recogniti

129 r protein inducing interferon beta (TRIF) or myeloid differentiation factor-88 (MyD88) and CX3CR1 kno

130 s for targeted disruption of TLR9, TLR3, and myeloid differentiation factor-88 (MyD88), and most of t

131 a), which in turn activate a well-described, myeloid-differentiation factor 88 (MYD88)-mediated, nucl

132 pression of chromatin-remodeling enzymes and myeloid differentiation factors.

133 F), which are required for growth arrest and myeloid differentiation following Hhex deletion.

134 e hematopoietic progenitors increased NK and myeloid differentiation, further supporting a role of TN

135 and primitive progenitors that blocks their myeloid differentiation, generating self-renewing leukem

136 tor of nuclear receptor signaling, represses myeloid differentiation genes and drives acute promyeloc

137 induced rapid proliferation and induction of myeloid-differentiation genes.

138 age 5-fold increase), cell-cycle arrest, and myeloid differentiation in AML cell lines and patient bl

139 However, restoring myeloid differentiation in C/EBPa mutants with inflammat

140 program of self-renewal and expansion toward myeloid differentiation in GMPs.

141 dihydroorotate dehydrogenase (DHODH) enables myeloid differentiation in human and mouse AML models.

142 ated factor 60b), as a critical regulator of myeloid differentiation in humans, mice, and zebrafish.

143 ate that S100A8 and S100A9 are regulators of myeloid differentiation in leukemia and have therapeutic

144 regulates the balance between erythroid and myeloid differentiation in model systems, providing insi

145 aling intermediates by flow cytometry during myeloid differentiation in MPN patients.

146 ompound from this series was found to induce myeloid differentiation in primary human IDH1 R132H AML

147 well understood, the spatial organization of myeloid differentiation in the bone marrow remains unkno

148 Activation of hematopoiesis and myeloid differentiation in tumor-bearing mice was induce

149 in regions as well as its ability to prevent myeloid differentiation in vivo.

150 ir self-renewal and markedly alters lymphoid/myeloid differentiation in vivo.

151 nscriptionally represses genes that regulate myeloid differentiation, including genes involved in cel

152 CR-ABL1 murine leukemia stem cells, arrested myeloid differentiation, inhibited genotoxic stress-indu

153 Together, these findings show that myeloid differentiation is a prerequisite for LSC format

154 oplasmic relocalization that occurred during myeloid differentiation is essential for PCNA antiapopto

155 ed cells to differentiation, suggesting that myeloid differentiation is promoted by loss of genome in

156 In this study, we show that accelerated myeloid differentiation, known as emergency myelopoiesis

157 t IFN-IL6-CEBP feed-forward loop, increasing myeloid differentiation linked to severe TB in humans.

158 ed metabolic state, which drives accelerated myeloid differentiation mainly through epigenetic deregu

159 ma balance and upregulated the expression of myeloid differentiation markers.

160 ing late sepsis might involve alterations in myeloid differentiation/maturation that generate circula

161 A transcription and consequent impairment of myeloid differentiation may contribute to leukemic trans

162 hat upregulation of GFI1 expression leads to myeloid differentiation morphologically and immunophenot

163 ibits all-trans-retinoic acid (ATRA)-induced myeloid differentiation of AML cells.

164 However, a role for CBFA2T3 in myeloid differentiation of AML has not been reported.

165 eated with quizartinib, we observed terminal myeloid differentiation of BM blasts in association with

166 evealed an increasing fitness advantage with myeloid differentiation of cells with mutated CALR.

167 rrest and apoptosis, and relieves a block in myeloid differentiation of FLT3-ITD(+) AML in vitro.

168 G-CSF)-induced proliferation with diminished myeloid differentiation of hematopoietic CD34(+) cells c

169 issues and was recently shown to inhibit the myeloid differentiation of hematopoietic stem/progenitor

170 Deletion of MLL4 enhances myelopoiesis and myeloid differentiation of leukaemic blasts, which prote

171 Silencing of METTL14 promotes terminal myeloid differentiation of normal HSPCs and AML cells an

172 G2/M cell-cycle progression and induction of myeloid differentiation of the leukemic blasts.

173 Understanding the process of myeloid differentiation offers important insights into b

174 volved in cell growth and proliferation, and myeloid differentiation pathways were among the most sig

175 profiling of pre-GMs, we identified distinct myeloid differentiation pathways: a pathway expressing t

176 Leukemia blasts show a myeloid differentiation phenotype when these lncRNAs wer

177 (2B) receptor antagonist resulted in altered myeloid differentiation potential.

178 also showed that toll-like receptor (TLR)-4/myeloid differentiation primary response (MyD)88 pathway

179 TLR4 and the key adaptor/signaling proteins myeloid differentiation primary response (MyD88), interl

180 emonstrate transcriptional repression of the Myeloid differentiation primary response 88 (Myd88) gene

181 Mutations in Toll-like receptor (TLR) and myeloid differentiation primary response 88 (MYD88) gene

182 s have acquired an oncogenic mutation in the myeloid differentiation primary response 88 (MYD88) gene

183 ptor adapter and major inflammatory mediator myeloid differentiation primary response 88 (MyD88) in p

184 9; 55.5%), especially those with concomitant myeloid differentiation primary response 88 (MYD88) muta

185 rigger inflammatory processes through either myeloid differentiation primary response 88 (MyD88) or T

186 significantly reduced upon gene knockdown of myeloid differentiation primary response 88 (MyD88), TAN

187 However, deficiency of the adaptor molecule myeloid differentiation primary response 88 (MyD88), whi

188 on-beta (TRIF) but less so for signaling via myeloid differentiation primary response 88 (MyD88).

189 hat the pro-inflammatory response depends on myeloid differentiation primary response 88 (MyD88).

190 The myeloid differentiation primary response 88 (MYD88)/inte

191 itochondrial antiviral signaling protein and myeloid differentiation primary response 88 adaptors, bu

192 omote monocyte recruitment through an MYD88 (myeloid differentiation primary response 88)-dependent m

193 iments show that the described phenomenon is myeloid differentiation primary response 88, IFN-gamma,

194 lity group box 1, nuclear factor kappa beta, myeloid differentiation primary response 88, interferon

195 tive effect of gedunin on MyD88-adapter-like/myeloid differentiation primary response 88- and TRIF-re

196 mechanism dependent on the adaptor molecule myeloid differentiation primary response gene (88) (MyD8

197 s that are dependent on the adaptor proteins Myeloid differentiation primary response gene (88) (MyD8

198 NA) levels of TLR4 and its adapter molecule, myeloid differentiation primary response gene (MYD) 88,

199 independently of CD14 and triggers canonical myeloid differentiation primary response gene 88 (MyD88)

200 have previously demonstrated that absence of myeloid differentiation primary response gene 88 (MyD88)

201 r the Toll-like receptor signaling component myeloid differentiation primary response gene 88 (MyD88)

202 o carcinogen-induced skin cancer, similar to myeloid differentiation primary response gene 88 (MyD88)

203 polysaccharide (LPS), a process dependent on myeloid differentiation primary response gene 88 (MYD88)

204 Deletion of the innate immune adaptor myeloid differentiation primary response gene 88 (MyD88)

205 Myeloid differentiation primary response gene 88 (MyD88)

206 LRs except TLR3, recruitment of the adapter, myeloid differentiation primary response gene 88 (MyD88)

207 In human myeloid differentiation primary response gene 88 (MyD88)

208 Using tissue-specific myeloid differentiation primary response gene 88 (Myd88)

209 ltiple innate signaling adaptor pathways for myeloid differentiation primary response gene 88 (MyD88)

210 IL1RL1, its coreceptor IL1RAcP, its adaptors myeloid differentiation primary response gene 88 (MyD88)

211 to mice deficient in the downstream adaptor, Myeloid differentiation primary response gene 88 (MYD88)

212 response were specifically upregulated in a myeloid differentiation primary response gene 88 (MyD88)

213 expression of Toll-like receptors (TLRs) and myeloid differentiation primary response gene 88 (MyD88)

214 M1-pUb linkages are added subsequently, and myeloid differentiation primary response gene 88 (MyD88)

215 signaling including the key adapter protein myeloid differentiation primary response gene 88 (MyD88)

216 or (TIR) domain-containing adapters, such as myeloid differentiation primary response gene 88 (MyD88)

217 containing adapter-inducing IFN-beta (TRIF), myeloid differentiation primary response gene 88 (MyD88)

218 RV-induced myositis/arthritis, we found that myeloid differentiation primary response gene 88 (Myd88)

219 he intracellular TLR signal adaptor known as myeloid differentiation primary response gene 88 (MyD88)

220 Myeloid differentiation primary response gene 88 (MyD88)

221 s dependent upon TLR4 and TLR7 signaling via myeloid differentiation primary response gene 88 (MyD88)

222 sion was induced by the oral microbiota in a myeloid differentiation primary response gene 88 (MyD88)

223 Biologic pathways mediated by myeloid differentiation primary response gene 88 (MyD88)

224 Myeloid differentiation primary response gene 88 (MyD88)

225 n is through the toll like receptor 4 (TLR4)/myeloid differentiation primary response gene 88 (MyD88)

226 and IL-1Rs recruit adaptor proteins, such as myeloid differentiation primary response gene 88 (MyD88)

227 (TLR; p < 0.001), IL-1 receptor (p = 0.001), myeloid differentiation primary response gene 88 (p = 0.

228 LPS increased adrenal myeloid differentiation primary response gene 88 and TLR

229 iver genes while also confirming the role of myeloid differentiation primary response gene 88 in the

230 Interestingly, myeloid differentiation primary response gene 88 knockou

231 tumour necrosis factor receptor (TNFR)-1/-2, Myeloid Differentiation primary response gene 88 or Toll

232 inly signal through the Toll-like receptor 4/myeloid differentiation primary response gene 88 pathway

233 ewise, targeted deletion of B-cell-intrinsic myeloid differentiation primary response gene 88 signali

234 R4) binds adapter proteins, including MyD88 (myeloid differentiation primary response gene 88) and Ma

235 molecule 1) but does not require the MyD88 (myeloid differentiation primary response gene 88) arm of

236 ontaining protein) is a member of the MyD88 (myeloid differentiation primary response gene 88) family

237 including the classical NF-kappaB and MYD88 (myeloid differentiation primary response gene 88) pathwa

238 CHOP (C/EBP homologous protein), and MyD88 (myeloid differentiation primary response gene 88), but n

239 f it lacks the innate defense protein MyD88 (myeloid differentiation primary response gene 88), or af

240 coli LPS provokes strong inflammatory MyD88 (myeloid differentiation primary response gene 88)-mediat

241 A expressions of NOD2, Toll-like receptor 2, myeloid differentiation primary response gene 88, and re

242 nd reduces eNOS expression via activation of myeloid differentiation primary response gene 88.

243 mally induce phosphorylation of CD19 through myeloid differentiation primary response gene-88 (MYD88)

244 for advanced glycation end products (RAGE), myeloid differentiation primary response gene-88, and tu

245 Skin injury of wild-type, ft/ft, and myeloid differentiation primary response gene-88-deficie

246 tyrosine phosphorylation, and recruitment of myeloid differentiation primary response protein (MyD) 8

247 blation in THP-1 cells impaired induction of myeloid differentiation primary response protein (MyD88)

248 r-2, alphavbeta3 integrin, CR3, and adaptors myeloid differentiation primary response protein 88 (MyD

249 Deletion of myeloid differentiation primary response protein 88 (MyD

250 Myeloid differentiation primary response protein 88 (MyD

251 Myeloid differentiation primary response protein 88 (MyD

252 Reanalysis of the array data set identified myeloid differentiation primary response protein 88 (MYD

253 ubiquitinating the innate signal transducer myeloid differentiation primary response protein 88 (MYD

254 LR2 polymorphism alters the functions of the myeloid differentiation primary response protein 88 (MyD

255 levels of Toll-like receptors (TLRs), CD14, myeloid differentiation primary response protein 88, and

256 (GC) responses, mice selectively deleted for myeloid differentiation primary-response protein 88 (MyD

257 acrophage ABCA1 also dampens proinflammatory myeloid differentiation primary-response protein 88-depe

258 terferon-beta (TRIF) but were independent of myeloid-differentiation primary response-gene 88 (MYD88)

259 expression changes in two divergent terminal myeloid differentiation processes, namely MAC and OC dif

260 of these cells results from activation of a myeloid differentiation program in bone marrow (BM) by a

261 hanges directly activate the common terminal myeloid differentiation programme.

262 am into macrophage-like cells by exposure to myeloid differentiation-promoting cytokines in vitro or

263 r of differentiation 14/Toll-like receptor 4/myeloid differentiation protein 2 (MD-2) complex.

264 n this study, we demonstrate that PTX3 binds myeloid differentiation protein 2 (MD-2) in vitro and ex

265 Herein, we show that rifampin binds to myeloid differentiation protein 2 (MD-2), the key corece

266 sory protein of Toll-like receptor 4 (TLR4), myeloid differentiation protein 2 (MD-2), thereby induci

267 Myeloid differentiation protein 2 (MD2) is a TLR4 corece

268 Increased expression of TLR4 and myeloid differentiation protein 2 (MD2) results in Akt p

269 recognition: (+)-norbinaltorphimine targets myeloid differentiation protein 2 and inhibits toll-like

270 tem following binding with the complex CD14, myeloid differentiation protein 2, and Toll-like recepto

271 The myeloid differentiation protein 88 (MyD88) adapter prote

272 two important TLR adaptor molecules, such as myeloid differentiation protein 88 (MyD88) and TRIF-rela

273 , including Toll-like receptor (TLR) 2/4 and myeloid differentiation protein 88 deficiency and neutro

274 orthotopic lung recipients in a TLR2/4- and myeloid differentiation protein 88-dependent fashion and

275 alein bound to the hydrophobic region of the myeloid differentiation protein-2 (MD-2) pocket and inhi

276 novel alternatively spliced isoform of human myeloid differentiation protein-2 (MD-2s) that competiti

277 lyses showed that GKY25 interferes with TLR4/myeloid differentiation protein-2 dimerization.

278 does not show DNA methylation changes during myeloid differentiation, provide evidence that 14q32 hyp

279 ontinuum of progenitors execute lymphoid and myeloid differentiation, rather than only uni-lineage pr

280 promotes CKMT1 expression by repressing the myeloid differentiation regulator RUNX1.

281 Here, we report that the myeloid differentiation-related transcription factor nuc

282 he role of Toll-like receptor (TLR) 2, TLR4, myeloid differentiation response gene 88, and Toll-IL-1

283 In the absence of TLR2, TLR4, myeloid differentiation response gene 88, or TRIF, the c

284 f zeste homolog 2 (EZH2) inhibitors promoted myeloid differentiation, suggesting EZH2 inhibitors may

285 ukaemia (AML) is characterized by a block in myeloid differentiation the stage of which is dependent

286 pendent activation of caspase 3 in promoting myeloid differentiation, the inhibition of caspase 3 blo

287 e to mutant HSC over normal HSC and promotes myeloid differentiation to engender a myeloproliferative

288 LL-AF9 and MOZ-TIF2 AML models, we show that myeloid differentiation to granulocyte macrophage progen

289 However, where IRF8 acts in the pathway of myeloid differentiation to influence PMN-MDSC production

290 Panobinostat triggered terminal myeloid differentiation via proteasomal degradation of A

291 Impaired myeloid differentiation was observed in LIG4-, but not A

292 To examine the role of GABP in myeloid differentiation, we generated mice in which Gabp

293 gulator of B-lymphoid development and blocks myeloid differentiation when ectopically expressed.

294 rowth of normal cord blood cells by inducing myeloid differentiation, whereas a certain level of RUNX

295 e vitamin A derivative retinoic acid (RA) in myeloid differentiation, whereas fewer studies explore t

296 zed wild-type IDH1 AML cells to ATRA-induced myeloid differentiation, whereas inhibition of 2-HG prod

297 MDL-1, a PU.1 transcriptional target during myeloid differentiation, which orchestrates osteoclast d

298 reactivates imprinted genes (without causing myeloid differentiation, which would confound downstream

299 y inducing cell-cycle arrest, apoptosis, and myeloid differentiation without general toxicity to norm

300 Finally, in addition to supporting myeloid differentiation, zebrafish Gcsf is required for